Top Abstract Purchase Related
Home
>
Node
>
Subnode

Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis

Smith, R.A.; Dupe, R.J.; English, P.D.; Green, J.

Thrombosis and Haemostasis 47(3): 269-274

1982

ISSN/ISBN: 0340-6245
PMID: 6214039
Document Number: 192834
A derivative of human lys-plasmin in which the active site has been reversibly acylated (BRL 26920; p-anisoyl human lys-plasmin) has been examined as a fibrinolytic agent in a previously described rabbit model of venous thrombosis and shown to be significantly more active and less fibrinogenolytic than free plasmin. A p-anisoylated derivative of a streptokinase (SK)-activated plasmin preparation was significantly less fibrinogenolytic in vivo than the non-acylated enzyme. Acylation increased the fibrinolytic activity of preparations of SK-plasmin activator complexes. BRL 26921, the active site anisoylated derivative of the primary 2-chain SK-plasminogen complex was the most potent fibrinolytic agent studied. SK-Val442-plasminogen complexes, free or acylated, were biologically inactive in this model and confirm the essential nature of fibrin binding processes for effective thrombolysis in vivo.

Document emailed within 1 workday
Secure & encrypted payments

Dupe, R.J.; English, P.D.; Smith, R.A.; Green, J. 1981: The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis Thrombosis and Haemostasis 46(2): 528-534
Martínez-Brotons, F.; Cairols, M.A. 1984: Thrombolytic treatment of deep venous thrombosis Sangre 29(4-C): 762-766
Kamal, A.K. 2006: Thrombolytic therapy in cerebral venous sinus thrombosis Jpma. Journal of the Pakistan Medical Association 56(11): 538-540
Pogliani, E.M.; Bozzani, A.; Radaelli, F.; Conte, D.; Bardella, M.T.; Colombi, M.; Quatrini, M. 1982: Thrombolytic therapy for venous thrombosis in patients with gastro-intestinal diseases Pharmatherapeutica 3(4): 268-273
Leonhardt, T.; Robertson, B. 1970: Thrombolytic treatment of acute venous thrombosis--and health care costs Lakartidningen 67(6): 586-588
Janssen, M.C.H.; Wollersheim, H.; Schultze-Kool, L.J.; Thien, T. 2005: Local and systemic thrombolytic therapy for acute deep venous thrombosis Netherlands Journal of Medicine 63(3): 81-90
Albuquerque, L.C.; Silveira, F.; Zago, A.J.; Bettio, J.; Petracco, J.B. 1997: Thrombolytic therapy in deep venous thrombosis. Initial clinical experience Arquivos Brasileiros de Cardiologia 68(2): 125-128
Gololobov, M.I.; Borisov, I.L.; Shviadas, V.K. 1987: Peptide synthesis catalyzed by proteases. Analysis of a kinetic model for enzymes with acyl-enzyme mechanism of action Biokhimiia 52(4): 584-591
Mannuccio Mannucci, P.; Altieri, D.; Mari, D. 1987: Thrombolytic therapy in acute deep venous thrombosis of the lower limbs: selection, indications and limits Minerva Chirurgica 42(23-24): 2031-2035
Bostwick, J.S.; Bentley, R.; Morgan, S.; Brown, K.; Chu, V.; Ewing, W.R.; Spada, A.P.; Pauls, H.; Perrone, M.H.; Dunwiddie, C.T.; Leadley, R.J. 1999: RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit Thrombosis and Haemostasis 81(1): 157-160
Fiessinger, J.N. 1994: Which antithrombotic agents should be prescribed in deep venous thrombosis of the limbs? Presse Medicale 23(11): 509-510
Arnljots, B.; Bergqvist, D.; Dahlbäck, B. 1994: Inhibition of microarterial thrombosis by activated protein C in a rabbit model Thrombosis and Haemostasis 72(3): 415-420
Abela, G.S.; Picon, P.D.; Friedl, S.E.; Gebara, O.C.; Miyamoto, A.; Federman, M.; Tofler, G.H.; Muller, J.E. 1995: Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model Circulation 91(3): 776-784
Prountjos, P.; Bastounis, E.; Hadjinikolaou, L.; Felekuras, E.; Balas, P. 1991: Superficial venous thrombosis of the lower extremities co-existing with deep venous thrombosis. a phlebographic study on 57 cases International Angiology: a Journal of the International Union of Angiology 10(2): 63-65
Koopman, K.; Uyttenboogaart, M.; Vroomen, P.C.A.J.; van der Meer, J.; De Keyser, J.; Luijckx, G-Jan. 2009: Risk factors for cerebral venous thrombosis and deep venous thrombosis in patients aged between 15 and 50 years Thrombosis and haemostasis 102(4): 620-622
Bonnet, J.; Colle, J.P.; Lorient-Roudaut, M.F.; Vergnes, C.; Haissaguerre, M.; Boisseau, M.R.; Bricaud, H. 1984: Efficacy and value of fibrinolytic agents in chronic proximal venous thrombosis of the lower limbs Archives des Maladies du Coeur et des Vaisseaux 77(9): 1033-1039
Tettamanti, R.; Alberico, P.; Porta, R. 1990: A model of venous thrombosis induced by stasis and Feiba in rabbits Bollettino della Societa Italiana di Biologia Sperimentale 66(5): 471-478
Wakefield, T.W.; Greenfield, L.J.; Rolfe, M.W.; DeLucia, A.; Strieter, R.M.; Abrams, G.D.; Kunkel, S.L.; Esmon, C.T.; Wrobleski, S.K.; Kadell, A.M. 1993: Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis Thrombosis and Haemostasis 69(2): 164-172
Cohen, M.L.; Robertson, D.W.; Bloomquist, W.E.; Wilson, H.C. 1992: LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis Journal of Pharmacology and Experimental Therapeutics 261(1): 202-208
Rebello, S.S.; Miller, B.V.; Basler, G.C.; Lucchesi, B.R. 1997: CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury Journal of Cardiovascular Pharmacology 29(2): 240-249